Overview
- 51 inspections across 51 sites are on record.
- 33 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-06-03.
At a glance
Inspections
51
Sites
51
Observations
33
Career since
Jan 2022
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Kimberly P. Cockerham, MD | 3 Jun 2026 | Human Drugs | On file |
| Summit Therapeutics, Inc. | 10 Apr 2026 | Human Drugs | |
| Noven Pharmaceuticals, Inc. | 13 Feb 2026 | Human Drugs | |
| Woongchae A. Lee, MD | 14 Jan 2026 | Medical Devices & Rad Health | |
| Andrew M. Schneider, MD | 7 Nov 2025 | Human Drugs | On file |
Sites inspected
Kimberly P. Cockerham, MDThe Villages, United States1 insp.
Summit Therapeutics, Inc.Palo Alto, United States1 insp.
Noven Pharmaceuticals, Inc.Miami, United States1 insp.
Woongchae A. Lee, MDBoca Raton, United States1 insp.
Andrew M. Schneider, MDTamarac, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Emily A Green12 shared
Emily C Caldwell2 shared
Chantae D Mitchell2 shared
Chinyere A Asanya2 shared
Ricardo Vela1 shared
Habacuc V Barrera1 shared
Ana P Barido1 shared
Sam Pepe1 shared
Asia D Clark1 shared
Richard A Lyght1 shared
Full investigator report
Get the verbatim findings behind Emily A Baldwin's 33 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site